SEC Form 4 · accession 0000919574-16-012045

Aegerion Pharmaceuticals, Inc. · AEGR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

10% Owner

Period of report

Mar 17, 2016

Accepted (ET)

Mar 21, 2016 · 4:48 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001338042

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.001 par value^F1	Mar 17, 2016	X	2,400	$7.50	A	3,512,691	D
Common Stock, $0.001 par value^F1	Mar 18, 2016	X	497,600	$7.50	A	4,010,291	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Put Options (obligation to buy)^F1	$7.50	Mar 17, 2016	X	24	D	Nov 10, 2015	Mar 18, 2016	Common Stock, $0.001 par value	2,400	D
Call Options (obligation to sell)^F1	$17.50	Mar 18, 2016	E	5,000	D	Nov 10, 2015	Mar 18, 2016	Common Stock, $0.001 par value	500,000	D
Put Options (obligation to buy)^F1	$7.50	Mar 18, 2016	X	4,976	D	Nov 10, 2015	Mar 18, 2016	Common Stock, $0.001 par value	497,600	D

F1The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.